Skip to content
OpenCapital
Get started

Outlook Therapeutics, Inc. OTLK Q1 2026 earnings

Reported May 15, 2026 · Before market open

Revenue$128.0KMiss by $4.3MDiluted EPS-$0.16Miss by $0.04
Revenue estimate$4.4M
EPS estimate-$0.12

Next report

Aug 13, 2026 (In 3 weeks)
Revenue estimate$4.8M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$128.0KMiss by $4.3M
Q4 2025-$1.2MMiss by $4.4MQ3 2025-$91.8KMiss by $5.9MQ2 2025$1.5MMiss by $4.3M

Diluted EPS

Q1 2026-$0.16Miss by $0.04
Q4 2025-$0.22Miss by $0.05Q3 2025-$0.22Beat by $0.04Q2 2025-$0.44Miss by $0.02Q1 2025-$0.40Beat by $0.15Q4 2024-$0.89Miss by $0.04

Ask the moment Outlook Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Outlook Therapeutics, Inc. report Q1 2026 earnings?
Outlook Therapeutics, Inc. (OTLK) reported Q1 2026 earnings on May 15, 2026 before market open.
What were Outlook Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Outlook Therapeutics, Inc. reported revenue of $128.0K and diluted EPS of $-0.16 for Q1 2026.
Did Outlook Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $4.4M by $4.3M. EPS missed the consensus estimate of $-0.12 by $0.04.
How did Outlook Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 60.0% from $-0.40.
Where can I find Outlook Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-060305) and the 10-Q periodic report (0001104659-26-062632) directly on SEC EDGAR. The filing index links above go to sec.gov.